11/25/15 - 06:49 AM EST
I give BioMarin a 5% chance of winning approval for drisapersen from the FDA following a negative advisory panel. I might be too generous.
11/24/15 - 07:39 AM EST
A panel of outside experts convened by the U.S. Food and Drug Administration will spend all day Tuesday reviewing drisapersen, BioMarin's experimental drug for Duchenne muscular dystrophy (DMD).
11/21/15 - 11:30 AM EST
The last thing the biotech industry needs today is another hit to investor credibility. Clovis isn't helping.
11/20/15 - 10:36 AM EST
It's almost cruel to see Al Mann being forced back into the CEO role at MannKind, but the company's near-total collapse demands it.
11/20/15 - 08:33 AM EST
The FDA is highly critical of BioMarin Pharmaceuticals' drisapersen, concluding that efficacy data from three clinical trials do 'not reach the level of substantial evidence' necessary for approval.
11/19/15 - 11:42 AM EST
BioMarin will almost certainly be halted all day Tuesday, so traders should watch Sarepta Therapeutics and PTC Therapeutics as proxies.
11/18/15 - 06:00 AM EST
On Nov. 24, a panel of outside experts convened by the U.S. Food and Drug Administration is set to review drisapersen, BioMarin's experimental drug for Duchenne muscular dystrophy.
11/16/15 - 10:06 AM EST
Clovis Oncology must submit additional clinical data on its targeted lung cancer drug rociletinib to U.S. regulators, delaying the approval review and putting the company further behind rival AstraZeneca.
11/13/15 - 09:36 AM EST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
11/12/15 - 03:09 PM EST
MannKind manages to raise a fraction of the money hoped from Israeli investment funds.